Sibylla Biotech S.r.l.

Sibylla Biotech S. r. l. is focused on drug discovery and development, particularly utilizing small molecule degraders to target protein degradation through innovative mechanisms.

Founded in Verona, Italy, Sibylla Biotech specializes in developing novel drug discovery technologies. The company raised EUR 23 mn in Series A funding on October 4, 2022, led by V-Bio Ventures and supported by other investors. Maria Barreca is the founder, while Lidia Pieri serves as CEO. Sibylla Biotech specializes in drug discovery and development, focusing on small molecule degraders that employ an innovative mechanism known as Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT).

This technology is applicable to therapeutic areas including oncology, neurodegenerative disorders, and COVID-19, and the company collaborates with various academic and pharmaceutical partners globally. In the year 2023, Sibylla Biotech reported no revenue, with an EBITDA of EUR -5,523,627. 1. The company generates revenue through collaborations and partnerships with pharmaceutical firms, focusing on milestone payments, licensing fees, and potential royalties connected to its proprietary drug discovery platform.

In October 2022, Sibylla Biotech raised EUR 23 mn in Series A funding, which will be utilized to expand its technology platform and accelerate its protein degradation initiatives. The company is actively working on new products aimed at enhancing therapeutic options in specific markets, including Europe, Asia, and North America. This funding will support these development efforts and strengthen its position in the global life sciences sector.